Highlights of the TLX Release: Q1 2024 Revenue and Business...

Highlights of the TLX Release: Q1 2024 Revenue and Business Update

If we breakdown line by line the R & B release, this TLX release by my count, as highlighted in Yellow showcases
no less than 15 plus updated or new information on TLX's current
earnings, it's new & current product progress, acquisitions & earnings forecasts.

The information released is in my opinion is " Momentous " to the future
stability of Telix...

NB: Add in the updated Broker reports .. compelling support to TLX's R & B Update.

DYOR & this is purely my Point of View...

---------------------------------------------------------------------------------------------------------------------------------------

Summary: Q1 2024 financial performance

The Company reports unaudited total revenue of US$114.9M1

(AU$175.0M) an increase of 18% on the prior quarter (US$97.1M2 or AU$148.1M).
Revenue was primarily generated from sales of Telix’s prostate cancer imaging product Illuccix®.

U.S. revenue grew by 18% to US$111.8M (US$95.1M in Q4 2023), compared to 11% growth
between Q3 2023 and Q4 2023.

Q1 2024 operational highlights
Telix continued to progress an extensive oncology pipeline:

• Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration
(FDA) to start the ProstACT GLOBAL Phase III trial of TLX5913 in the U.S.

• Continued enrolment of ProstACT GLOBAL at Australian sites with 13 new sites onboarded
during the quarter • TLX101-CDx (Pixclara™4
,
18F-floretyrosine or 18F-FET) has been granted Fast Track designation
for PET 5 characterisation of glioma 6

. Concurrently, Telix is finalising its U.S. New Drug Application (NDA) with submission on track for H1 2024

• The Biologics License Application (BLA) for TLX250-CDx (Zircaix®4 89Zr-DFO-girentuximab) is
progressing under a Breakthrough Therapy rolling review submission and is due for completion
by end-May. Telix has requested a Priority Review7 for Zircaix®4

, and

• Progression of a NDA for a novel prostate cancer imaging agent, with a submission goal of this
quarter.

Supply chain and manufacturing bolstered by recent acquisitions Telix continued to augment
its product development and manufacturing capabilities with two
strategic acquisitions:

• ARTMS, a company which specialises in the physics, chemistry and materials science of
cyclotron-produced radionuclides. The acquisition brings an advanced cyclotron-based
diagnostic and therapeutic isotope production platform, manufacturing plant and stockpile of
ultra-pure rare metals8
.
• IsoTherapeutics, a leading radiochemistry and bioconjugation firm. The acquisition further
enhances Telix’s in-house development capabilities and expands Telix’s U.S. manufacturing
footprint with particular focus on bioconjugation and isotope processing9


Full year 2024 outlook and guidance

Telix reaffirms guidance provided on 22 February 2024 for full year revenue expected to be in the
range of US$445M to $465M (AU$675M to $705M at current exchange rates), representing an
approximate 35-40% increase versus 2023.

The Company also reaffirms guidance that research and development (R&D) investment is expected
to increase by 40-50% for full year 2024 (compared with 2023) including external and internal costs
funded by operating cash flow and broadly in line with revenue growth.